Sanguisorba officinalis L. and Its Derived Compounds Inhibit Liver Fibrosis in TGF-β1-treated LX-2 Hepatic Stellate Cells
- Authors
- Nam, Yunseong; Kim, Myung Suk; Erdenebileg, Saruul; Nho, Chu Won
- Issue Date
- 2022-10-20
- Publisher
- The Korean Society of Food Science and Nutrition
- Citation
- 2022 KFN International Symposium and Annual Meeting
- Abstract
- Liver fibrosis, a further stage of non-alcoholic steatohepatitis (NASH) is known to be significantly less likely to recover than NASH. Sanguisorba officinalis L. (SO) is a plant that has been reported as anti-inflammatory, antioxidant, with beneficial effects in improving metabolic diseases such as obesity and diabetes. Gallic acid (GA), Ziyuglycoside I (ZG1), and Ziyuglycoside II (ZG2) are well known compounds present in SO root ethanol extract (SOEE). We validated the inhibitory effect of SOEE on liver fibrosis in a previous study using an animal model. In this study, we investigated which derived compounds drive the inhibitory effect of liver fibrosis using TGF-β1-treated LX-2 hepatic stellate cells. By quantitative RT-PCR and western blot, we found that SOEE and its derived compounds (GA, ZG1 and ZG2) inhibit the expression of liver fibrosis-related genes and regulate MAPK signaling pathways. These results suggest that SOEE and its derived compounds may be effective in alleviating the liver fibrosis by mediating MAPK in LX-2 cells.
- URI
- https://pubs.kist.re.kr/handle/201004/76583
- Appears in Collections:
- KIST Conference Paper > 2022
- Files in This Item:
There are no files associated with this item.
- Export
- RIS (EndNote)
- XLS (Excel)
- XML
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.